Variation in innate immunity genes and risk of multiple myeloma

Hematological Oncology

Volumn 29, Issue 1, 2011, Pages 42-46

  Purdue, Mark P ^a   Lan, Qing ^a   Menashe, Idan ^a   Zheng, Tongzhang ^b   Zhang, Yawei ^b   Yeager, Meredith ^a,c   Hosgood, H Dean ^a   Zahm, Shelia H ^a   Chanock, Stephen J ^a,c   Rothman, Nathaniel ^a   Baris, Dalsu ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SAIC FREDERICK INC   (United States)

Author keywords

Epidemiology; Genetics; Myeloma

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RISK; FEMALE; GENETIC VARIABILITY; GENOTYPE; HUMAN; INNATE IMMUNITY; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HEPATOCYTE GROWTH FACTOR; HUMANS; IMMUNITY, INNATE; MIDDLE AGED; MULTIPLE MYELOMA; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, CCR7; RISK FACTORS;

EID: 79952351630     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.954     Document Type: Article

References (47)

1. De Roos AJ, Baris D, Weiss NS, Herrinton LJ, Multiple myeloma. In Cancer Epidemiology and Prevention (3rd edn), Schottenfeld D, Fraumeni JF (eds). Oxford University Press: New York, 2006; 919-945.
2. Kastrinakis NG, Gorgoulis VG, Foukas PG, Dimopoulos MA, Kittas C. Molecular aspects of multiple myeloma. Ann Oncol 2000; 11: 1217-1228.
3. Maldonado JE, Kyle RA. Familial myeloma. Report of eight families and a study of serum proteins in their relatives. Am J Med 1974; 57: 875-884.
4. Shoenfeld Y, Berliner S, Shaklai M, Gallant LA, Pinkhas J. Familial multiple myeloma. A review of thirty-seven families. Postgrad Med J 1982; 58: 12-16.
5. Brown LM, Linet MS, Greenberg RS, et al. Multiple myeloma and family history of cancer among blacks and whites in the U.S. Cancer 1999; 85: 2385-2390.
6. Landgren O, Linet MS, McMaster ML, Gridley G, Hemminki K, Goldin LR. Familial characteristics of autoimmune and hematologic disorders in 8, 406 multiple myeloma patients: a population-based case-control study. Int J Cancer 2006; 118: 3095-3098.
7. Kristinsson SY, Goldin LR, Bjorkholm M, Koshiol J, Turesson I, Landgren O. Genetic and immune-related factors in the pathogenesis of lymphoproliferative and plasma cell malignancies. Haematologica 2009; 94: 1581-1589.
8. Cozen W, Gebregziabher M, Conti DV, et al. Interleukin-6-related genotypes, body mass index, and risk of multiple myeloma and plasmacytoma. Cancer Epidemiol Biomarkers Prev 2006; 15: 2285-2291.
9. Brown EE, Lan Q, Zheng T, et al. Common variants in genes that mediate immunity and risk of multiple myeloma. Int J Cancer 2007; 120: 2715-2722.
10. Birmann BM, Tamimi RM, Giovannucci E, et al. Insulin-like growth factor-1- and interleukin-6-related gene variation and risk of multiple myeloma. Cancer Epidemiol Biomarkers Prev 2009; 18: 282-288.
11. Forrest MS, Skibola CF, Lightfoot TJ, et al. Polymorphisms in innate immunity genes and risk of non-Hodgkin lymphoma. Br J Haematol 2006; 134: 180-183.
12. Nieters A, Beckmann L, Deeg E, Becker N. Gene polymorphisms in Toll-like receptors, interleukin-10, and interleukin-10 receptor alpha and lymphoma risk. Genes Immun 2006; 7: 615-624.
13. Purdue MP, Lan Q, Wang SS, et al. A pooled investigation of Toll-like receptor gene variants and risk of non-Hodgkin lymphoma. Carcinogenesis 2009; 30: 275-281.
14. Landgren O, Zhang Y, Zahm SH, Inskip P, Zheng T, Baris D. Risk of multiple myeloma following medication use and medical conditions: a case-control study in Connecticut women. Cancer Epidemiol Biomarkers Prev 2006; 15: 2342-2347.
15. Carlson CS, Eberle MA, Rieder MJ, Yi Q, Kruglyak L, Nickerson DA. Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet 2004; 74: 106-120.
16. Westfall PH, Zaykin DV, Young SS. Multiple tests for genetic effects in association studies. Methods Mol Biol 2002; 184: 143-168.
17. Chen BE, Sakoda LC, Hsing AW, Rosenberg PS. Resampling-based multiple hypothesis testing procedures for genetic case-control association studies. Genet Epidemiol 2006; 30: 495-507.
18. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 1995; 57: 289-300.
19. Churchill GA, Doerge RW. Empirical threshold values for quantitative trait mapping. Genetics 1994; 138: 963-971.
20. Stranger BE, Nica AC, Forrest MS, et al. Population genomics of human gene expression. Nat Genet 2007; 39: 1217-1224.
21. Yagci M, Sucak GT, Haznedar R. Fibrinolytic activity in multiple myeloma. Am J Hematol 2003; 74: 231-237.
22. Kristinsson SY, Fears TR, Gridley G, et al. Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. Blood 2008; 112: 3582-3586.
23. Corre J, Mahtouk K, Attal M, et al. Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. Leukemia 2007; 21: 1079-1088.
24. Kwaan HC, Wang J, Svoboda K, Declerck PJ. Plasminogen activator inhibitor 1 may promote tumour growth through inhibition of apoptosis. Br J Cancer 2000; 82: 1702-1708.
25. Chen Y, Kelm RJ Jr, Budd RC, Sobel BE, Schneider DJ. Inhibition of apoptosis and caspase-3 in vascular smooth muscle cells by plasminogen activator inhibitor type-1. J Cell Biochem 2004; 92: 178-188.
26. Bajou K, Noel A, Gerard RD, et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 1998; 4: 923-928.
27. McMahon GA, Petitclerc E, Stefansson S, et al. Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. J Biol Chem 2001; 276: 33964-33968.
28. Palmieri D, Lee JW, Juliano RL, Church FC. Plasminogen activator inhibitor-1 and -3 increase cell adhesion and motility of MDA-MB-435 breast cancer cells. J Biol Chem 2002; 277: 40950-40957.
29. Chazaud B, Ricoux R, Christov C, Plonquet A, Gherardi RK, Barlovatz-Meimon G. Promigratory effect of plasminogen activator inhibitor-1 on invasive breast cancer cell populations. Am J Pathol 2002; 160: 237-246.
30. Morange PE, Saut N, Alessi MC, et al. Association of plasminogen activator inhibitor (PAI)-1 (SERPINE1) SNPs with myocardial infarction, plasma PAI-1, and metabolic parameters: the HIFMECH study. Arterioscler Thromb Vasc Biol 2007; 27: 2250-2257.
31. Lange LA, Reiner AP, Carty CL, Jenny NS, Cushman M, Lange EM. Common genetic variants associated with plasma fibrin D-dimer concentration in older European- and African-American adults. J Thromb Haemost 2008; 6: 654-659.
32. Seidel C, Borset M, Turesson I, Abildgaard N, Sundan A, Waage A. Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group. Blood 1998; 91: 806-812.
33. Iwasaki T, Hamano T, Ogata A, Hashimoto N, Kitano M, Kakishita E. Clinical significance of vascular endothelial growth factor and hepatocyte growth factor in multiple myeloma. Br J Haematol 2002; 116: 796-802.
34. Ludek P, Hana S, Zdenek A, et al. Treatment response to bortezomib in multiple myeloma correlates with plasma hepatocyte growth factor concentration and bone marrow thrombospondin concentration. Eur J Haematol 2009; 84: 332-336.
35. Pour L, Svachova H, Adam Z, et al. Pretreatment hepatocyte growth factor and thrombospondin-1 levels predict response to high-dose chemotherapy for multiple myeloma. Neoplasma 2010; 57: 29-34.
36. Derksen PW, de Gorter DJ, Meijer HP, et al. The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma. Leukemia 2003; 17: 764-774.
37. Vande BI, Asosingh K, Allegaert V, et al. Bone marrow endothelial cells increase the invasiveness of human multiple myeloma cells through upregulation of MMP-9: evidence for a role of hepatocyte growth factor. Leukemia 2004; 18: 976-982.
38. Bussolino F, Di Renzo MF, Ziche M, et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 1992; 119: 629-641.
39. Standal T, Abildgaard N, Fagerli UM, et al. HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma. Blood 2007; 109: 3024-3030.
40. Yanovitch T, Li YJ, Metlapally R, Abbott D, Viet KN, Young TL. Hepatocyte growth factor and myopia: genetic association analyses in a Caucasian population. Mol Vis 2009; 15: 1028-1035.
41. Dieu MC, Vanbervliet B, Vicari A, et al. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J Exp Med 1998; 188: 373-386.
42. Hirao M, Onai N, Hiroishi K, et al. CC chemokine receptor-7 on dendritic cells is induced after interaction with apoptotic tumor cells: critical role in migration from the tumor site to draining lymph nodes. Cancer Res 2000; 60: 2209-2217.
43. Mashino K, Sadanaga N, Yamaguchi H, et al. Expression of chemokine receptor CCR7 is associated with lymph node metastasis of gastric carcinoma. Cancer Res 2002; 62: 2937-2941.
44. Kodama J, Hasengaowa Kusumoto T, et al. Association of CXCR4 and CCR7 chemokine receptor expression and lymph node metastasis in human cervical cancer. Ann Oncol 2007; 18: 70-76.
45. Trentin L, Miorin M, Facco M, et al. Multiple myeloma plasma cells show different chemokine receptor profiles at sites of disease activity. Br J Haematol 2007; 138: 594-602.
46. Wacholder S, Chanock S, Garcia-Closas M, El GL, Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 2004; 96: 434-442.
47. Bhatti P, Sigurdson AJ, Wang SS, et al. Genetic variation and willingness to participate in epidemiologic research: data from three studies. Cancer Epidemiol Biomarkers Prev 2005; 14: 2449-2453.